The battle over the trillion-dollar weight-loss bonanza
Novo Nordisk and Eli Lilly are making blockbuster drugs. Can they maintain their lead?
WEIGHT-LOSS drugs called GLP-1 agonists help users shed fat, and with it the negative health effects of obesity. This can have life-changing effects for the people who take them. It is also increasingly affecting the lives of corporate citizens. Since June 2021, when Wegovy, the first GLP-1 slimming jab, was launched in America, the market value of WW (formerly Weight Watchers) has crashed by 90%. On February 28th Oprah Winfrey announced that she would leave the dieting firm’s board and sell all her shares in order to avoid a conflict of interest around her use of GLP-1s. Food giants such as Nestlé are already planning for a future where the drugs dampen demand for sugary snacks. Bosses of consumer-goods firms brought up weight-loss drugs twice as often in the last full set of quarterly earnings calls, in late 2023, as they had in the previous one (see chart 1).
This article appeared in the Business section of the print edition under the headline "Slim pharma"
Business March 9th 2024
- The battle over the trillion-dollar weight-loss bonanza
- Brain-boosting substances are all the rage
- More women are getting onto corporate boards. Good
- OpenAI’s legal battles are not putting off customers—yet
- Can Bayer recover from its chronic pain?
- How can firms pass on tacit knowledge?
- Apple is right not to rush headlong into generative AI
More from Business
Does Perplexity’s “answer engine” threaten Google?
Taking aim at one of the best business models of all times
How not to work on a plane
Hours without interruption and work to do. What could go wrong?
Why does BHP want Anglo American?
Its $39bn takeover offer is the latest in a string of mining mega-mergers